In sum, the data highlight the potential ability of PDX models to guide the development of clinical trials for UTUC patients and suggest that antibody drug conjugates targeting HER2 may be more effective in UTUC patients than selective HER2 kinase inhibitors. The gene discussed is ERBB2; the disease is renal pelvis/ureter urothelial carcinoma.